ProCE Banner Activity

SOLAR-3D: Wk 144 Results of Switching to DTG/3TC in Virologically Suppressed Heavily Treatment–Experienced People With HIV

Conference Coverage
Slideset

In open-label SOLAR-3D study, no confirmed virologic failures were observed when switching from 2-, 3-, or 4-drug ART to DTG/3TC, despite prior virologic failure and prior or current M184V/I.

Released: July 26, 2024

Expiration: July 25, 2025

Share

Faculty

Angela Davies

Angela Davies, MD

Assistant Professor of Medicine
UC Davis Cancer Center
Sacramento, CA

Amit “Mickey” Dhir

Amit “Mickey” Dhir, MBA, MSN, AGNP-C, AAHIVS

Infectious Disease Nurse Practitioner
Chase Brexton Health Care
Baltimore, Maryland

PT Faculty

Georgia Colangelo

Georgia Colangelo, RN, BSN, OCN

Collaborative Practice Nurse
Hillman Cancer Center
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society  

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner